The CEO has highlighted the success by ProQR in transitioning from Phase 1 to pivotal clinical trials in 'as little as 3 months'. PYCs drug candidate for retinitis pigmentosa is scheduled to enter IND enabling studies in H1 2020. It may have taken 13 years to get within reach of the clinic but progress could quickly accelerate once clinical studies commence.
Perth partnership targets childhood blindness and $1 billion market, page-7
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 18.8¢ | $963.9K | 4.978M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2692 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 445208 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |